Eli Lilly and Co. (NYSE:LLY) shares are trading lower Wednesday, pulling back after the stock notched an all-time high just last week, even as the company separately reported positive real-world data on its weight-loss drug Zepbound. Here’s what you should know.
Eli Lilly stock is showing notable weakness. What’s behind LLY decline?
Eli Lilly Pulls Back After Hitting Record Highs Last Week
Eli Lilly shares touched an all-time intraday high of $1,292.65 and closed at a record $1,280.34 on Aug. 19, before easing off those levels in the sessions since. Shares have traded in a range of $1,180.01 to $1,235.775 more recently, still well within the stock’s 52-week range of $694.23 to $1,292.65, according to Benzinga Pro.
The pullback looks like a normal consolidation after a strong run to fresh highs rather than a reaction to any specific negative news.
